Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.

Publication Type:

Journal Article

Authors:

Barr, Paul M; Li, Hongli; Spier, Catherine; Mahadevan, Daruka; LeBlanc, Michael; Ul Haq, Mansoor; Huber, Bryan D; Flowers, Christopher R; Wagner-Johnston, Nina D; Horwitz, Steven M; Fisher, Richard I; Cheson, Bruce D; Smith, Sonali M; Kahl, Brad S; Bartlett, Nancy L; Friedberg, Jonathan W

Source:

Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015)

Abstract:

Aurora A kinase (AAK) is upregulated in highly proliferative lymphomas, suggesting its potential as a therapeutic target. Alisertib is a novel oral AAK inhibitor without adverse safety signals in early-phase studies that demonstrated preliminary activity in T-cell lymphoma. This phase II study was conducted to further investigate the efficacy of alisertib in relapsed or refractory peripheral T-cell non-Hodgkin lymphoma (PTCL).